Q-omics provides the consensus-scored OR52P1P profile across patient tissues and cancer cell-line models. OR52P1P expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, OR52P1P is differentially expressed in 5, with the highest sampling consensus in LUSC. Additionally, OR52P1P RNA expression shows 10,794 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight SKCM, LUSC, and LAML as cancer lineages where OR52P1P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR52P1P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR52P1P survival associations across molecular data types. OR52P1P RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR52P1P RNA expression–survival associations across cancer types. High OR52P1P expression shows unfavorable associations in DLBC, ACC, LUAD, LUSC and LAML, but favorable associations in SKCM. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify SKCM as the clearest survival context for OR52P1P RNA expression.
This table summarizes OR52P1P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for OR52P1P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR52P1P shows lower tumor expression in LUSC, UCEC and KICH and higher tumor expression in KIRC and STAD. The LUSC box plot shows higher OR52P1P RNA expression in normal versus tumor tissue (log2 FC = −0.100, t-test p < 0.001).
This table shows molecular features associated with OR52P1P in patient tissues and cancer cell lines. In patient samples, OR52P1P shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
